Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report

被引：0
|
作者：
Ogawa, Shoko [1 ]
Konishi, Ken-ichiro [1 ]
Tanaka, Kiyoshi [2 ]
Takayasu, Hajime [1 ]
Uematsu, Yoshimasa [1 ]
Ito, Takashi [3 ]
Takahashi, Hiroyuki [4 ]
Kumamoto, Yusuke [1 ]
机构：
[1] Kitasato Univ, Sch Med, Dept Gen Pediat & Hepatobiliary Pancreat Surg, Sagamihara, Kanagawa, Japan
[2] Kitasato Univ, Sch Med, Res & Dev Ctr New Med Frontiers, Dept Adv Med,Div Pediat Surg, Sagamihara, Kanagawa, Japan
[3] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa, Japan
[4] Kitasato Univ, Sch Allied Hlth Sci, Dept Pathol, Sagamihara, Kanagawa, Japan
来源：
FRONTIERS IN PEDIATRICS | 2024年 / 12卷
关键词：
glucagon-like peptide-2 analog; immune effect; short bowel syndrome; eosinophilic gastrointestinal diseases; teduglutide; COWS MILK ALLERGY; ANTIINFLAMMATORY ACTIONS; INFLAMMATION; PATHWAYS; BARRIER;
D O I：
10.3389/fped.2024.1457824
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
We successfully treated a 4-year-old girl with short bowel syndrome and eosinophilic enterocolitis with teduglutide, a glucagon-like peptide-2 analog. Her eosinophilic enterocolitis was cured without relapse, and we were able to increase enteral nutrition. We found that teduglutide had an anti-inflammatory effect in this patient with eosinophilic gastrointestinal disease associated with short bowel syndrome. This report is the first to describe use of teduglutide in the treatment of eosinophilic gastrointestinal disease.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] The effect of central glucagon-like peptide-2 on arterial blood pressure in rats
    Okada, Saori
    Hamada, Sachie
    Oka, Jun-iciro
    NEUROSCIENCE RESEARCH, 2011, 71 : E159 - E159
  • [32] Cholecystitis following the initiation of glucagon-like peptide-2 analogue for short bowel syndrome: A case report
    Goto, Yudai
    Masumoto, Kouji
    Jimbo, Takahiro
    Sasaki, Takato
    Tanaka, Yasunari
    Shirane, Kazuki
    NUTRITION IN CLINICAL PRACTICE, 2024, 39 (05) : 1247 - 1250
  • [33] Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers
    Bolognani, Federico
    Kruithof, Annelieke C.
    Schulthess, Pascal
    Machacek, Matthias
    de Kam, Marieke L.
    Bergmann, Kirsten R.
    van Gent, Max
    Moerland, Matthijs
    Crenn, Pascal
    Greig, Gerard
    Gal, Pim
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 386 (02): : 129 - 137
  • [34] The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters
    Bremholm, Lasse
    Hornum, Mads
    Andersen, Ulrik B.
    Holst, Jens Juul
    REGULATORY PEPTIDES, 2010, 159 (1-3) : 67 - 71
  • [35] In vivo and in vitro degradation of glucagon-like peptide-2 in humans
    Hartmann, B
    Harr, MB
    Jeppesen, PB
    Wojdemann, M
    Deacon, CF
    Mortensen, PB
    Holst, JJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08): : 2884 - 2888
  • [36] Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
    Drucker, Daniel J.
    Yusta, Bernardo
    ANNUAL REVIEW OF PHYSIOLOGY, VOL 76, 2014, 76 : 561 - 583
  • [37] Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function
    Brubaker, Patricia L.
    COMPREHENSIVE PHYSIOLOGY, 2018, 8 (03) : 1185 - 1210
  • [38] Glucagon-like peptide-2 increases BDNF expression in glia
    Yoshitake, Yumiko
    Iwai, Takashi
    Oka, Jun-Ichiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 124P - 124P
  • [39] Distribution of glucagon-like peptide-2 in normal colonic tissue
    Caddy, G
    Johnston, C
    Ardill, J
    Pogue, K
    Collins, J
    Gardiner, K
    Watson, P
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2003, 38 (07) : 798 - 799
  • [40] Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2
    L'Heureux, MC
    Brubaker, PL
    ANNALS OF MEDICINE, 2001, 33 (04) : 229 - 235
12345